These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34173019)

  • 1. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing.
    Jurmeister P; Vollbrecht C; Jöhrens K; Aust D; Behnke A; Stenzinger A; Penzel R; Endris V; Schirmacher P; Fisseler-Eckhoff A; Neumann J; Kirchner T; Büttner R; Merkelbach-Bruse S; Kreipe H; Jonigk D; Jochum W; Rodriguez R; Dietel M; Horst D; Hummel M; von Laffert M
    Virchows Arch; 2021 Aug; 479(2):247-255. PubMed ID: 34173019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
    Wang B; Chen R; Wang C; Guo J; Yuan M; Chen H; Xia X; Zhong D
    Hum Pathol; 2021 Aug; 114():90-98. PubMed ID: 34019866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test.
    von Laffert M; Penzel R; Schirmacher P; Warth A; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Oct; 9(10):1464-9. PubMed ID: 25170635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
    Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
    Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
    Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
    Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effectiveness of RNA in-situ hybridization for detecting lung adenocarcinoma with anaplastic lymphoma kinase rearrangement.
    Nakajima N; Yoshizawa A; Kondo K; Rokutan-Kurata M; Hirata M; Furuhata A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Fujimoto M; Date H; Haga H
    Histopathology; 2017 Jul; 71(1):143-149. PubMed ID: 28231386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.
    Chang WC; Kim HK; Shin BK
    Oncol Rep; 2020 Jan; 43(1):218-228. PubMed ID: 31746406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods.
    Siebolts U; Pappesch R; Bauer M; Dietmaier W; Ernst M; Haak A; Hartmann N; Ilm K; Kalbourtzis S; Krause T; Kazdal D; Schorle H; Utpatel K; Merkelbach-Bruse S
    Virchows Arch; 2024 Sep; 485(3):519-526. PubMed ID: 39120655
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Canterbury CR; Fernandes H; Crapanzano JP; Murty VV; Mansukhani MM; Shu CA; Szabolcs M; Saqi A
    JTO Clin Res Rep; 2021 Oct; 2(10):100223. PubMed ID: 34746883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and therapeutic evaluation of ALK rearrangements in non-small-cell lung cancer.
    Zhao R; Guo L; Zhang B; Zhao J; Xiang C; Chen S; Shao J; Zhu L; Ye M; Han Y
    J Pathol Clin Res; 2022 Nov; 8(6):538-549. PubMed ID: 35848751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?
    Tachon G; Cortes U; Richard S; Martin S; Milin S; Evrard C; Lamour C; Karayan-Tapon L
    Cancer Med; 2019 Dec; 8(18):7556-7566. PubMed ID: 31651105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
    Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
    J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.